Diphenhydramine/lorazepam/zolpidem
| Combination of | |
|---|---|
| Diphenhydramine | Antihistamine (histamine H1 receptor antagonist) and anticholinergic (muscarinic acetylcholine receptor antagonist) |
| Lorazepam | Benzodiazepine (GABAA receptor positive allosteric modulator) |
| Zolpidem | Z drug/nonbenzodiazepine (GABAA receptor positive allosteric modulator) |
| Clinical data | |
| Other names | SM-1; SM1 |
| Routes of administration | Oral[1] |
Diphenhydramine/lorazepam/zolpidem (developmental code name SM-1) is a combination of the antihistamine and anticholinergic diphenhydramine, the benzodiazepine lorazepam, and the Z drug/nonbenzodiazepine zolpidem which is or was under development for the treatment of insomnia.[1][2][3][4][5] It is taken orally.[1] Both lorazepam and zolpidem are GABAA receptor positive allosteric modulators.[6] The combination was originated by Sequential Medicine and is under development by Eusol Biotech.[1] As of October 2024, it is in phase 3 clinical trials for insomnia.[1] However, another source lists the drug as having been discontinued.[2]
See also
References
- ^ a b c d e "Diphenhydramine/lorazepam/zolpidem". AdisInsight. 22 October 2024. Retrieved 15 January 2026.
- ^ a b "Delving into the Latest Updates on Diphenhydramine/Lorazepam/Zolpidem with Synapse". Synapse. 8 May 2025. Retrieved 15 January 2026.
- ^ Dahl T, Chen LB, Scheinin M, Suopanki-Lalowski J, Valge M, Puhakka A, et al. (November 2019). "Pharmacodynamic and pharmacokinetic profile of SM-1, a triple-drug combination to increase total sleep time". Human Psychopharmacology. 34 (6) e2716. doi:10.1002/hup.2716. PMID 31794072.
- ^ Dahl T, Chen LB, Zammit G, Ahmad M, Roth T (November 2019). "Efficacy of SM-1 in a transient insomnia model". Human Psychopharmacology. 34 (6) e2713. doi:10.1002/hup.2713. PMID 31837050.
- ^ Dahl T, Zammit G, Ahmad M, Rosenberg R, Chen LB, Roth T (January 2022). "Efficacy of the triple-combination SM-1 in a 5-h phase advance transient insomnia model". Sleep and Biological Rhythms. 20 (1): 47–52. doi:10.1007/s41105-021-00338-5. PMC 10897638. PMID 38469063.
- ^ Krystal AD (December 2023). "Insomnia medications: History, characteristics, and guidelines for optimal use in clinical practice". Journal of Sleep Research. 32 (6) e14084. doi:10.1111/jsr.14084. PMID 37940337.